Neurizon Therapeutics Ltd. Announces Promising Preclinical Results for NUZ-001 in Zebrafish Model of Huntington's Disease

Reuters
06/16
Neurizon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Ltd. Announces Promising Preclinical Results for NUZ-001 in Zebrafish Model of Huntington's Disease

Neurizon Therapeutics Ltd., a clinical-stage biotech company, has announced promising preclinical results for their drug candidate NUZ-001 in a zebrafish model of Huntington's disease. The study demonstrated that NUZ-001 and its active metabolite, NUZ-001 Sulfone, exhibited significant neuroprotective effects. The treatment successfully prevented developmental and morphological abnormalities, protected against neuronal cell death, restored haemoglobin production, and rescued BDNF expression following the knockdown of the Htt protein. These findings underscore NUZ-001's potential as a platform therapy targeting core neurodegenerative mechanisms. Neurizon plans to initiate additional validation studies in mammalian models of Huntington's disease to further explore its therapeutic potential. These results were presented on June 16, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN10836) on June 16, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10